{
    "clinical_study": {
        "@rank": "30085", 
        "acronym": "NewLira", 
        "arm_group": [
            {
                "arm_group_label": "Liraglutide", 
                "arm_group_type": "Active Comparator", 
                "description": "1.8 mg"
            }, 
            {
                "arm_group_label": "Saline", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to investigate the effect and safety of liraglutide 1.8 mg once\n      daily compared to placebo for 52 weeks on change in beta-cell function in patients with\n      newly diagnosed type 1 diabetes as an adjunctive therapy to insulin treatment."
        }, 
        "brief_title": "Liraglutide in Newly Onset Type 1 Diabetes.", 
        "completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Diabetes Mellitus, Type 1", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 1"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Type 1 diabetes according to WHO criteria diagnosed \u2264 6 weeks before visit 0\n\n          -  Age 18 - 40 years - both inclusive\n\n          -  Postprandial C-peptide > 0.2 nmol/l following sustacal meal test\n\n          -  Able to understand the written patient information and to give informed consent\n\n        Exclusion Criteria:\n\n          -  Type 2 diabetes\n\n          -  Body mass index <20 kg/m2\n\n          -  Pregnancy or unwillingness to use safe contraceptives\n\n          -  Compromised kidney function (eGFR < 60 ml/min/1,73m2), dialysis or kidney\n             transplantation at visit 0\n\n          -  Liver disease with elevated plasma alanine aminotransferase (ALT) > three times the\n             upper limit of normal at visit 0"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "40 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "80", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 14, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01879917", 
            "org_study_id": "2012-005317-39", 
            "secondary_id": [
                "2012-005317-39", 
                "U1111-1137-3221"
            ]
        }, 
        "intervention": {
            "arm_group_label": "Liraglutide", 
            "intervention_name": "Liraglutide", 
            "intervention_type": "Drug", 
            "other_name": "Victoza"
        }, 
        "intervention_browse": {
            "mesh_term": "Glucagon-Like Peptide 1"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "c-peptide", 
            "insulin", 
            "hypoglycemia", 
            "Newly onset", 
            "Diabetes", 
            "Type 1", 
            "Beta cell", 
            "Autoimmune", 
            "Glucagon", 
            "Meal test"
        ], 
        "lastchanged_date": "November 28, 2013", 
        "location": {
            "contact": {
                "email": "tfdejgaard@dadlnet.dk", 
                "last_name": "Thomas F Dejgaard, MD", 
                "phone": "+45 26796103"
            }, 
            "contact_backup": {
                "email": "sten.madsbad@hvh.regionh.dk", 
                "last_name": "Sten Madsbad, Professor", 
                "phone": "+45 21691911"
            }, 
            "facility": {
                "address": {
                    "city": "Hvidovre", 
                    "country": "Denmark", 
                    "state": "Capital", 
                    "zip": "2650"
                }, 
                "name": "Dep. of Endocrinology, Hvidovre University Hospital"
            }, 
            "investigator": [
                {
                    "last_name": "Thomas F Dejgaard, MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Christian S. S. Frandsen, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Denmark"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomised, Double-blind, Placebo-controlled, Parallel Group, Multi-centre Trial of Liraglutide Treatment in Subjects With Newly Diagnosed Type 1 Diabetes.", 
        "other_outcome": [
            {
                "description": "To investigate the effect of liraglutide as compared to placebo for 52 weeks as an adjunctive therapy to insulin treatment on change in: HbA1c.", 
                "measure": "HbA1c", 
                "safety_issue": "No", 
                "time_frame": "52 weeks"
            }, 
            {
                "description": "To investigate the effect of liraglutide as compared to placebo for 52 weeks as an adjunctive therapy to insulin treatment on change ininsulin dose.", 
                "measure": "Insulin dose", 
                "safety_issue": "No", 
                "time_frame": "52 weeks"
            }, 
            {
                "description": "To investigate the effect of liraglutide as compared to placebo for 52 weeks as an adjunctive therapy to insulin treatment on change in weight.", 
                "measure": "Weight", 
                "safety_issue": "No", 
                "time_frame": "52 weeks"
            }, 
            {
                "description": "To investigate the effect of liraglutide as compared to placebo for 52 weeks as an adjunctive therapy to insulin treatment on change in length of insulin remission period.", 
                "measure": "Remission period", 
                "safety_issue": "No", 
                "time_frame": "52 weeks"
            }, 
            {
                "description": "To investigate the effect of liraglutide as compared to placebo for 52 weeks as an adjunctive therapy to insulin treatment on change in frequency of hypoglycaemic events.", 
                "measure": "Hypoglycemia", 
                "safety_issue": "No", 
                "time_frame": "52 weeks"
            }
        ], 
        "overall_contact": {
            "email": "tfdejgaard@dadlnet.dk", 
            "last_name": "Thomas F Dejgaard, MD", 
            "phone": "+45 26796103"
        }, 
        "overall_contact_backup": {
            "email": "sten.madsbad@hvh.regionh.dk", 
            "last_name": "Sten Madsbad, Professor, DMSc.", 
            "phone": "+45 21691911"
        }, 
        "overall_official": {
            "affiliation": "Hvidovre University Hospital", 
            "last_name": "Sten Madsbad, Professor", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Denmark: Ethics Committee", 
                "Denmark: Danish Medicines Agency", 
                "Denmark: Danish Dataprotection Agency"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To investigate the effect and safety of liraglutide 1.8 mg once daily compared to placebo for 52 weeks on change in beta-cell function in patients with newly diagnosed type 1 diabetes as an adjunctive therapy to insulin treatment.", 
            "measure": "Beta-cell function", 
            "safety_issue": "No", 
            "time_frame": "52 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01879917"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Hvidovre University Hospital", 
            "investigator_full_name": "Thomas Dejgaard", 
            "investigator_title": "MD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "To investigate the effect of liraglutide as compared to placebo for 52 weeks as an adjunctive therapy to insulin treatment on change in Postprandial glucagon levels following sustacal meal test.", 
            "measure": "Postprandial glucagon", 
            "safety_issue": "No", 
            "time_frame": "52 weeks"
        }, 
        "source": "Hvidovre University Hospital", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Steno Diabetes Center", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Hillerod Hospital, Denmark", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Bispebjerg Hospital", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Odense University Hospital", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Aarhus University Hospital", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Aalborg Universityhospital", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Hospital of South West Denmark", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Hvidovre University Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}